Kimia Appoints Imran S. Haque as Chief Technology Officer
Investor - People | Mar 18, 2025 | Column Group LLC/The
Kimia Therapeutics, a biotechnology company focused on creating a chemical atlas for human disease treatment, has appointed Imran S. Haque, Ph.D., as its Chief Technology Officer. Haque, who previously served as Senior Vice President of AI and Digital Sciences at Recursion, brings nearly two decades of experience in chemistry, biology, and machine learning. At Kimia, he will oversee the development of the ATLAS technology platform, a high-throughput system integrating chemistry, machine learning, and genome editing to accelerate drug discovery. Kimia, a spin-out from Carmot Therapeutics, aims to leverage Chemotype Evolution technology to pioneer new therapies, particularly in cancer and immunology. Haque's background includes leadership roles at Freenome and Counsyl, contributing to the application of machine learning in diagnostics and genetic testing. Kimia's efforts are supported by The Column Group, envisioning a future techbio landscape driven by rapid experimentation and advanced computation.
Sectors
- Biotechnology
- Artificial Intelligence
- Healthcare
Geography
- United States – Kimia Therapeutics is based in Berkeley, California, and Imran S. Haque's previous roles were at U.S.-based companies.
Industry
- Biotechnology – Kimia Therapeutics operates in the biotechnology sector, focusing on drug discovery and development through its ATLAS platform.
- Artificial Intelligence – The appointment of Imran Haque as CTO to advance Kimia's AI-driven drug discovery platform highlights the role of AI in this initiative.
- Healthcare – Kimia Therapeutics aims to develop therapies for cancer and immunological disorders, contributing to the broader healthcare industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Kimia Therapeutics | Target Company | Company | A biotechnology company developing a drug discovery platform called ATLAS. |
| Imran S. Haque, Ph.D. | Chief Technology Officer | Person | Appointed as CTO of Kimia, overseeing the ATLAS technology platform development. |
| The Column Group | Private Equity Firm | Company | PE firm that partnered in the spin-out of Kimia from Carmot Therapeutics. |
| Carmot Therapeutics | Spun-out Company | Company | From which Kimia was spun out, contributing Chemotype Evolution technology. |
| Recursion | Former Employer | Company | Imran S. Haque's former company where he led AI and digital sciences. |